Go Pro
→ The retirement stock I'd buy before Nvidia today (From Chaikin Analytics) (Ad)tc pixel Free GENF Stock Alerts

Genflow Biosciences (GENF) Competitors

Genflow Biosciences logo
GBX 2.10 +0.05 (+2.44%)
As of 11:59 AM Eastern
Compare

GENF vs. HVO, HEMO, COIL, C4XD, and DDDD

Should you buy Genflow Biosciences stock or one of its competitors? Genflow Biosciences's main competitors and comparable companies include hVIVO (HVO), Hemogenyx Pharmaceuticals (HEMO), Roquefort Therapeutics (COIL), C4X Discovery (C4XD), and 4D pharma (DDDD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Genflow Biosciences compare to hVIVO?

hVIVO (LON:HVO) and Genflow Biosciences (LON:GENF) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, profitability, institutional ownership, earnings, dividends, risk and analyst recommendations.

In the previous week, hVIVO had 4 more articles in the media than Genflow Biosciences. MarketBeat recorded 4 mentions for hVIVO and 0 mentions for Genflow Biosciences. hVIVO's average media sentiment score of 0.18 beat Genflow Biosciences' score of 0.00 indicating that hVIVO is being referred to more favorably in the media.

Company Overall Sentiment
hVIVO Neutral
Genflow Biosciences Neutral

hVIVO has higher revenue and earnings than Genflow Biosciences. hVIVO is trading at a lower price-to-earnings ratio than Genflow Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
hVIVO£46.77M1.01£17.84M-£0.87N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

12.7% of hVIVO shares are owned by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are owned by institutional investors. 4.9% of hVIVO shares are owned by company insiders. Comparatively, 25.8% of Genflow Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

hVIVO presently has a consensus target price of GBX 15, suggesting a potential upside of 118.34%. Given hVIVO's stronger consensus rating and higher possible upside, equities research analysts plainly believe hVIVO is more favorable than Genflow Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
hVIVO
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Genflow Biosciences
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

hVIVO has a beta of 1.706, indicating that its stock price is 71% more volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.268, indicating that its stock price is 127% more volatile than the broader market.

hVIVO has a net margin of -12.48% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat hVIVO's return on equity.

Company Net Margins Return on Equity Return on Assets
hVIVO-12.48% -14.65% 11.97%
Genflow Biosciences -170.64%332.06%-58.66%

Summary

hVIVO beats Genflow Biosciences on 10 of the 15 factors compared between the two stocks.

How does Genflow Biosciences compare to Hemogenyx Pharmaceuticals?

Hemogenyx Pharmaceuticals (LON:HEMO) and Genflow Biosciences (LON:GENF) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

Hemogenyx Pharmaceuticals has a beta of 1.501, suggesting that its stock price is 50% more volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.268, suggesting that its stock price is 127% more volatile than the broader market.

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Hemogenyx PharmaceuticalsN/A -2,807.75% -37.79%
Genflow Biosciences -170.64%332.06%-58.66%

Genflow Biosciences is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are held by institutional investors. 10.0% of Hemogenyx Pharmaceuticals shares are held by insiders. Comparatively, 25.8% of Genflow Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.

Company Overall Sentiment
Hemogenyx Pharmaceuticals Neutral
Genflow Biosciences Neutral

Summary

Hemogenyx Pharmaceuticals beats Genflow Biosciences on 5 of the 9 factors compared between the two stocks.

How does Genflow Biosciences compare to Roquefort Therapeutics?

Genflow Biosciences (LON:GENF) and Roquefort Therapeutics (LON:COIL) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

In the previous week, Genflow Biosciences' average media sentiment score of 0.00 equaled Roquefort Therapeutics'average media sentiment score.

Company Overall Sentiment
Genflow Biosciences Neutral
Roquefort Therapeutics Neutral

Genflow Biosciences has a beta of 2.268, indicating that its share price is 127% more volatile than the broader market. Comparatively, Roquefort Therapeutics has a beta of 0.05, indicating that its share price is 95% less volatile than the broader market.

0.1% of Genflow Biosciences shares are held by institutional investors. Comparatively, 1.9% of Roquefort Therapeutics shares are held by institutional investors. 25.8% of Genflow Biosciences shares are held by insiders. Comparatively, 36.1% of Roquefort Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Genflow Biosciences has a net margin of -170.64% compared to Roquefort Therapeutics' net margin of -57,057.07%. Genflow Biosciences' return on equity of 332.06% beat Roquefort Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Genflow Biosciences-170.64% 332.06% -58.66%
Roquefort Therapeutics -57,057.07%-18.71%-15.86%

Genflow Biosciences is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A

Summary

Roquefort Therapeutics beats Genflow Biosciences on 5 of the 9 factors compared between the two stocks.

How does Genflow Biosciences compare to C4X Discovery?

C4X Discovery (LON:C4XD) and Genflow Biosciences (LON:GENF) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk.

52.1% of C4X Discovery shares are held by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are held by institutional investors. 27.1% of C4X Discovery shares are held by company insiders. Comparatively, 25.8% of Genflow Biosciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, C4X Discovery's average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.

Company Overall Sentiment
C4X Discovery Neutral
Genflow Biosciences Neutral

C4X Discovery has a beta of 0.23, meaning that its stock price is 77% less volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.268, meaning that its stock price is 127% more volatile than the broader market.

C4X Discovery has a net margin of 42.81% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat C4X Discovery's return on equity.

Company Net Margins Return on Equity Return on Assets
C4X Discovery42.81% 55.38% 28.04%
Genflow Biosciences -170.64%332.06%-58.66%

C4X Discovery has higher revenue and earnings than Genflow Biosciences. Genflow Biosciences is trading at a lower price-to-earnings ratio than C4X Discovery, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
C4X Discovery£24.68M0.00£10.57M£0.04N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

Summary

C4X Discovery beats Genflow Biosciences on 8 of the 10 factors compared between the two stocks.

How does Genflow Biosciences compare to 4D pharma?

4D pharma (LON:DDDD) and Genflow Biosciences (LON:GENF) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

4D pharma has a beta of 2.63, indicating that its share price is 163% more volatile than the broader market. Comparatively, Genflow Biosciences has a beta of 2.268, indicating that its share price is 127% more volatile than the broader market.

In the previous week, 4D pharma's average media sentiment score of 0.00 equaled Genflow Biosciences'average media sentiment score.

Company Overall Sentiment
4D pharma Neutral
Genflow Biosciences Neutral

Genflow Biosciences has lower revenue, but higher earnings than 4D pharma. Genflow Biosciences is trading at a lower price-to-earnings ratio than 4D pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
4D pharma£718K0.00-£31.94M-£15.40N/A
Genflow BiosciencesN/AN/A-£1.76M-£0.33N/A

26.8% of 4D pharma shares are owned by institutional investors. Comparatively, 0.1% of Genflow Biosciences shares are owned by institutional investors. 12.2% of 4D pharma shares are owned by company insiders. Comparatively, 25.8% of Genflow Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

4D pharma has a net margin of 0.00% compared to Genflow Biosciences' net margin of -170.64%. Genflow Biosciences' return on equity of 332.06% beat 4D pharma's return on equity.

Company Net Margins Return on Equity Return on Assets
4D pharmaN/A -89.48% -42.64%
Genflow Biosciences -170.64%332.06%-58.66%

Summary

4D pharma beats Genflow Biosciences on 6 of the 10 factors compared between the two stocks.

Get Genflow Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for GENF and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

GENF vs. The Competition

Export
MetricGenflow BiosciencesBiotechnology IndustryHealthcare SectorLON Exchange
Market Cap£11.90M£3.99B£7.20B£2.89B
Dividend YieldN/A3.61%2.53%6.17%
P/E Ratio-6.3312.25272.63364.82
Price / SalesN/A1,349.92620.8183,676.90
Price / Cash3.00105.2976.9827.89
Price / Book8.4616.1912.856.75
Net Income-£1.76M-£22.72M£3.47B£5.89B
7 Day Performance1.50%-1.18%-0.22%-0.78%
1 Month Performance25.52%12.75%8.04%2.38%
1 Year Performance134.64%53.86%25.08%22.66%

Genflow Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GENF
Genflow Biosciences
N/AGBX 2.10
+2.4%		N/A+133.3%£11.90MN/AN/A5
HVO
hVIVO
1.6578 of 5 stars		GBX 6.43
-1.8%		GBX 15
+133.5%		-32.2%£45.02M£46.77MN/AN/A
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 588
+1.4%		N/A-36.4%£39.98MN/AN/A14
COIL
Roquefort Therapeutics
N/AGBX 9.33
-1.8%		N/A-41.7%£39.82MN/AN/A9
C4XD
C4X Discovery
N/AN/AN/AN/A£30.27M£24.68M300.0049

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:GENF) was last updated on 9/2/2026 by MarketBeat.com Staff.
From Our Partners
Under $1… and Wall Street already knows about it
On August 19th, Bitcoin exploded 23% in a matter of days… triggering nearly $3 billion in short liquidations, ...
Crypto 101 Media | Sponsoredtc pixel
Gold Explorer Sits Between Barrick’s Nevada Giants
Barrick Mining has spent decades building one of Nevada's richest gold districts, anchored by Fourmile, Goldru...
Wall Street Logic | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel
A weekly dividend fund holding Nvidia and Palantir
CrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...
Investors Alley | Sponsoredtc pixel
The retirement stock I'd buy before Nvidia today
In 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...
Chaikin Analytics | Sponsoredtc pixel
Rickards Predicts: Trump to buy tiny $2 stock?
Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the la...
Paradigm Press | Sponsoredtc pixel
Why Boston Ships In Natural Gas It Already Has at Home
A tanker called the Iberica Knutsen once sailed 2,272 miles from Trinidad and Tobago to deliver liquefied natu...
Porter & Company | Sponsoredtc pixel
#1 Stock to Own as Trump Launches Historic Mission Backing "Medical AI"
The federal government is throwing its full support behind a new class of AI technology, in what's being calle...
Stansberry Research | Sponsoredtc pixel